Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)

Affiliations

• ¹ Departments of Pediatrics and Neurology and Neurosurgery, McGill University, Montreal, Canada. maryam.oskoui@mcgill.ca.
• ² Department of Neurology, Stanford University, Palo Alto, CA, USA.
• ³ Neuromuscular Reference Center, UZ Gent, Ghent, Belgium.
• ⁴ Centre de Référence des Maladies Neuromusculaires et Service de Neurologie Pédiatrique, Queen Fabiola Children's University Hospital, Université Libre de Bruxelles, ULB, Brussels, Belgium.
• ⁵ Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
• ⁶ Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, CIBERER-ISC III, Barcelona, Spain.
• ⁷ Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.
• ⁸ Department of Pediatric Physical Medicine and Rehabilitation, Hôpital Mère Enfant, CHU-Lyon, Lyon, France.
• ⁹ Neuromyogen Institute, CNRS UMR 5310-INSERM U1217, Université de Lyon, Lyon, France.
• ¹⁰ The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London and Great Ormond Street Hospital Trust, London, UK.
• ¹¹ Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
• ¹² Neuromuscular Reference Centre, Department of Paediatrics and Child Neurology, University Hospitals Leuven, Leuven, Belgium.
• ¹³ Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany.
• ¹⁴ Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
• ¹⁵ I-Motion-Hôpital Armand Trousseau, Paris, France.
• ¹⁶ MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, UK.
• ¹⁷ Division of Child Neurology, Centre de Références des Maladies Neuromusculaires, University Hospital Liège and University of Liège, Liège, Belgium.
• ¹⁸ Pharma Development, Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
• ¹⁹ PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
• ²⁰ Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
• ²¹ Roche Products Ltd, Welwyn Garden City, UK.
• ²² Pharma Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.